Login to Your Account



Intercell Looking for 'Renewal' After S. Aureus Vaccine Failure

By Jennifer Boggs


Thursday, June 9, 2011
Intercell AG's prophylactic vaccine against Staphylococcus aureus infections is out of the picture, two months after a Phase II/III study was halted for futility, with the news sending shares of the Austrian biotech falling 22 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription